340B Drug Pricing Program
The House Ways and Means Committee today voted to advance a bill, H.R. 9504, the Tax-Exempt Hospitals Transparency Act, that would add reporting requirements for nonprofit hospitals’ Schedule H IRS forms.
Join the AHA 340B Advocacy Alliance on July 8 at 3 p.m. ET for the latest updates on the 340B Drug Pricing Program and opportunities to engage directly with AHA 340B team members.
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a legislative discussion draft that would make several changes to the 340B Drug Pricing Program.
HRSA seeks input on 340B Rebate Model.
The AHA today issued a statement denouncing unprecedented actions taken by Eli Lilly to deny 340B Drug Pricing Program discounts to certain 340B hospitals that do not meet its unilateral data requirements.
AHA can confirm that Eli Lilly has taken the extraordinary action of denying 340B discounts. Congress should immediately use its oversight authority and demand HHS take a position on drug companies’ attempts to hijack the 340B program through burdensome claims-data demands.
HRSA seeks input on 340B Rebate Model.
Cookeville Regional Medical Center (CRMC) is an independent, city-owned, not-for-profit, 309-bed regional referral medical center serving more than 350,000 residents across 14 counties.
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.
Eli Lilly Moves to Deny 340B Pricing Over Data Requirements; AHA Urges Federal Action